Top 5 Drug Type | Count |
---|---|
Small molecule drug | 12 |
Unknown | 1 |
Target |
Mechanism CDA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date07 Jul 2020 |
Target |
Mechanism DNMT1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date02 May 2006 |
Target |
Mechanism ADA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date11 Oct 1991 |
Start Date31 Jul 2024 |
Sponsor / Collaborator |
Start Date07 Mar 2024 |
Sponsor / Collaborator |
Start Date14 Jul 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cedazuridine ( CDA ) | Acute Myeloid Leukemia More | Phase 3 Clinical |
Decitabine/Cedazuridine ( CDA x DNMT1 ) | Myelodysplastic Syndromes More | Phase 3 |
Azacitidine/Cedazuridine ( DNMT1 ) | Philadelphia chromosome positive chronic myelogenous leukemia More | Phase 3 |
Guadecitabine Sodium ( DNMT1 ) | Acute Myeloid Leukemia More | Phase 3 |
ASTX-029 ( ERK1 x ERK2 ) | Solid tumor More | Phase 2 |